metformin and orlistat

metformin has been researched along with orlistat in 69 studies

Research

Studies (69)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	3 (4.35)	18.2507
2000's	29 (42.03)	29.6817
2010's	28 (40.58)	24.3611
2020's	9 (13.04)	2.80

Authors

Authors	Studies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Andres, E; Blicklé, JF; Brogard, JM; Neyrolles, N	1
Wilding, J	1
Bray, GA	1
Greenway, F	1
Capuzzi , DM; Cohn, G; Valdes, G	1
BascilTutuncu, N; Gokcel, A; Gumurdulu, Y; Guvener, N; Karakose, H; Melek Ertorer, E; Tanaci, N	1
Anderson, JW; Aronne, L; Doyle, M; Foreyt, J; Hollander, P; Klein, S; Leiter, L; Miles, JM; Wadden, T	1
Sanders, TA; Taylor, D; Werneke, U	1
Noda, M	1
Bouche, C; Goldfine, AB	1
Conlon, C; Dawson, D	1
Laville, M	1
Kumar, S; Peter, P	1
Jermendy, G	1
Aucott, L; Avenell, A; Broom, J; Brown, TJ; Campbell, MK; Grant, AM; Jung, RT; Poobalan, A; Smith, WC; Stearns, SC	1
Balci, MK; Coban, E; Sari, R; Yazicioglu, G	1
Atkin, SL; Holding, S; Jayagopal, V; Jennings, PE; Kilpatrick, ES	1
Bugianesi, E; Marchesini, G; Marzocchi, R; Villanova, N	1
Anderson, DC	1
Atkin, SL; González, S; Kilpatrick, ES	1
Berne, C	1
Moreno Sánchez, D	1
Athyros, VG; Elisaf, M; Mikhailidis, DP	1
Desilets, AR; Dunican, KC; Montalbano, JK	1
Al-Zaman, Y; Aylwin, S	1
Aronne, LJ; Neff, LM	1
Acosta, MC; Levin, FR; Manubay, J	1
Barnett, A; Rahim, A; Samat, A	1
Atkin, SL; Cho, LW; Coady, AM; Keevil, BG; Kilpatrick, ES	1
Harrison, SA; Kashi, MR; Torres, DM	1
Amer, S; Ledger, WL; Li, TC; Metwally, M	1
Fonseca, VA	1
Bryson, A; Groot, Gde H; Hallam, R; Hickling, RI; Kopelman, P; Palmer, R; Rissanen, A; Rossner, S; Toubro, S	1
Delkos, D; Dinas, K; Kalaitzakis, E; Kandaraki, EA; Katsikis, I; Koiou, E; Panidis, D; Tziomalos, K	1
Aflatoonian, A; Ghandi, S; Moghaddam, MH; Tabibnejad, N	1
Smahelová, A	1
Decristofaro, C; Elliott, L; Hopkins, KF	1
Delkos, D; Kalaitzakis, E; Kandaraki, EA; Katsikis, I; Koiou, E; Panidis, D; Tziomalos, K; Vosnakis, C	1
Bray, GA; Ryan, DH	1
Armstrong, SC; Dolinsky, DH; Kinra, S	1
Kautzky-Willer, A; Lemmens-Gruber, R	1
Carter, P; Chilton, M; Davies, MJ; Dunkley, A; Gray, LJ; Khunti, K	1
Henry, L; Mehta, R; Mishra, A; Reyes, MJ; Younossi, ZM	1
Boyle, J; De Courten, B; Joham, A; Naderpoor, N; Shorakae, S; Teede, HJ	1
Christie, D; Clifford, S; Jamieson, L; Shield, JP; Smith, F; Viner, RM; White, B; Wong, IC	1
Ganesh, S; Rustgi, VK	1
Graff, SK; Mario, FM; Spritzer, PM; Ziegelmann, P	1
Garland, B; Hastings, E; Himes, R; Taylor, SA	1
Bogdański, P; Grzymisławska, M; Kargulewicz, A; Kręgielska-Narożna, M; Kujawska-Łuczak, M; Musialik, K; Swora-Cwynar, E; Szulińska, M	1
Atkinson, G; Baur, L; Corpeleijn, E; Ells, LJ; Finer, N; Mead, E; Metzendorf, MI; O'Malley, C; Richter, B	1
Shaw, E	1
Ahmed, AT; Almasri, J; Alsawas, M; Asi, N; Farah, W; Mohammed, K; Murad, MH; Prokop, LJ; Rajjo, T	1
Burda, BU; Eder, M; Evans, CV; Lozano, P; O'Connor, EA; Walsh, ES	1
Ahmed, L; Atkin, SL; Coady, AM; Dakroury, Y; Dawson, AJ; Elshewehy, AMM; Kilpatrick, ES; Sathyapalan, T	1
Gu, M; Mueck, AO; Ruan, X; Song, J; Wang, H; Wang, L	2
Bogdanski, P; Grzymislawska, M; Kregielska-Narozna, M; Kujawska-Luczak, M; Markuszewski, L; Musialik, K; Skrypnik, D; Swora-Cwynar, E; Szulinska, M	1
Alfieri, C; Tanner, JE	1
Anand, K; Dua, K; Gupta, G; Kumar Chellappan, D; Kumar Jha, N; Singh, Y; Thangavelu, L	1
Duan, L; Gong, FY; Miao, H; Pan, H; Wang, LJ; Yang, HB; Zhao, YX; Zhu, HJ	1
Abdalla, MA; Al-Rifai, RH; Atkin, SL; Deshmukh, H; Östlundh, L; Sahebkar, A; Sathyapalan, T; Shah, N	1
Asadipooya, K; Bakhtiari, M	1
Liu, H; Wu, F; Xie, Y; Yin, S; Zhang, Q; Zhao, G	1
Ahmad, S; Alanazi, J; Alanazi, M; Alharby, TN; Anwar, S; Elamine, BA; Hussain, A; Hussain, T; Itumalla, R; Mohamed, OA; Unnisa, A; Younes, KM	1
Attanasio, R; Borretta, G; Busetto, L; Chianelli, M; Disoteo, OE; Grimaldi, F; Nicolucci, A; Paoletta, A; Papini, E; Persichetti, A; Samperi, I; Scoppola, A	1
Coskun, H; Demır, AS; Ersöz, HÖ; Gunay, YE; Karakullukçu, S; Kişioğlu, SV; Kocak, M; Nuhoglu, I; Tufekcı, D	1

Reviews

37 review(s) available for metformin and orlistat

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016
[Current status of the treatment of type 2 diabetes mellitus. The revival of insulin-resistance drugs]. La Revue de medecine interne, 1999, Volume: 20 Suppl 3 Topics: Administration, Oral; Chromans; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Exercise; Fenfluramine; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Lactones; Lipase; Metformin; Orlistat; Peroxisome Proliferators; Pioglitazone; Rosiglitazone; Thiazoles; Thiazolidinediones; Troglitazone	1999
Drug treatment of obesity. Bailliere's best practice & research. Clinical endocrinology & metabolism, 1999, Volume: 13, Issue:1 Topics: Androgen Antagonists; Androgens; Anti-Obesity Agents; Appetite Depressants; Caffeine; Central Nervous System Stimulants; Energy Metabolism; Enzyme Inhibitors; Ephedrine; Humans; Hypoglycemic Agents; Lactones; Lipase; Metformin; Obesity; Orlistat; Patient Selection	1999
Obesity medications and the treatment of type 2 diabetes. Diabetes technology & therapeutics, 1999,Fall, Volume: 1, Issue:3 Topics: Acarbose; Anti-Obesity Agents; Appetite Depressants; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Reducing; Humans; Hypoglycemic Agents; Lactones; Life Style; Metformin; Obesity; Orlistat; Weight Loss	1999
Pathophysiology and treatment of the dyslipidemia of insulin resistance. Current cardiology reports, 2001, Volume: 3, Issue:5 Topics: Cardiovascular Diseases; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Lactones; Life Style; Lipase; Metformin; Niacin; Orlistat; Risk Factors	2001
Options for pharmacological management of obesity in patients treated with atypical antipsychotics. International clinical psychopharmacology, 2002, Volume: 17, Issue:4 Topics: Amantadine; Antipsychotic Agents; Cimetidine; Cyclobutanes; Fluoxetine; Fructose; Humans; Lactones; Metformin; Nizatidine; Obesity; Orlistat; Topiramate; Weight Gain	2002
[Primary prevention of diabetes mellitus by pharmacological intervention]. Nihon rinsho. Japanese journal of clinical medicine, 2002, Volume: 60 Suppl 9 Topics: Acarbose; Angiotensin-Converting Enzyme Inhibitors; Chromans; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lactones; Metformin; Orlistat; Pravastatin; Primary Prevention; Ramipril; Thiazoles; Thiazolidinediones; Troglitazone	2002
Prevention of type 2 diabetes: are we ready? Minerva medica, 2003, Volume: 94, Issue:1 Topics: Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lactones; Life Style; Lipase; Metformin; Orlistat; Thiazoles; Thiazolidinediones; Troglitazone	2003
[Is it possible to prevent type 2 diabetes?]. Annales d'endocrinologie, 2003, Volume: 64, Issue:3 Suppl Topics: Acarbose; Adult; Aged; Diabetes Mellitus, Type 2; Diet; Exercise; Female; Glucose Intolerance; Humans; Hypoglycemic Agents; Lactones; Life Style; Male; Metformin; Middle Aged; Orlistat; Prospective Studies; Randomized Controlled Trials as Topic; Risk Factors; Weight Loss	2003
[Is type-2 diabetes mellitus preventable?]. Orvosi hetilap, 2003, Sep-28, Volume: 144, Issue:39 Topics: Acarbose; Angiotensin-Converting Enzyme Inhibitors; Anti-Obesity Agents; Antihypertensive Agents; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Exercise; Global Health; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Incidence; Lactones; Life Style; Metabolic Syndrome; Metformin; Orlistat; Prevalence; Primary Prevention; Risk Factors	2003
Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement. Health technology assessment (Winchester, England), 2004, Volume: 8, Issue:21 Topics: Anti-Obesity Agents; Behavior Therapy; Caloric Restriction; Cost-Benefit Analysis; Cyclobutanes; Diet, Fat-Restricted; Humans; Hypoglycemic Agents; Lactones; Markov Chains; Metformin; Obesity; Orlistat; Physical Fitness; Randomized Controlled Trials as Topic; Risk Factors	2004
Non-alcoholic fatty liver disease/non-alcoholic steatohepatitis (NAFLD/NASH): treatment. Best practice & research. Clinical gastroenterology, 2004, Volume: 18, Issue:6 Topics: Antioxidants; Cholagogues and Choleretics; Cytoprotection; Enzyme Inhibitors; Fatty Liver; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lactones; Life Style; Lipase; Metformin; Orlistat; Phlebotomy; Thiazolidinediones; Ursodeoxycholic Acid	2004
Pharmacologic prevention or delay of type 2 diabetes mellitus. The Annals of pharmacotherapy, 2005, Volume: 39, Issue:1 Topics: Acarbose; Chromans; Diabetes Mellitus, Type 2; Humans; Hypoglycemic Agents; Lactones; Meta-Analysis as Topic; Metformin; Orlistat; Randomized Controlled Trials as Topic; Thiazolidinediones; Troglitazone	2005
[Medical management of primary nonalcoholic fatty liver disease]. Medicina clinica, 2005, Jun-18, Volume: 125, Issue:3 Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fatty Liver; Heptanoic Acids; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Metabolic Syndrome; Metformin; Obesity; Orlistat; Prevalence; Pyrroles; Rosiglitazone; Thiazolidinediones; Troglitazone	2005
Pharmacotherapeutic options for overweight adolescents. The Annals of pharmacotherapy, 2007, Volume: 41, Issue:9 Topics: Adolescent; Anti-Obesity Agents; Clinical Trials as Topic; Cyclobutanes; Humans; Hypoglycemic Agents; Lactones; Metformin; Obesity; Orlistat; Overweight	2007
Emerging concepts in the medical and surgical treatment of obesity. Frontiers of hormone research, 2008, Volume: 36 Topics: Adipose Tissue; Amyloid; Anticonvulsants; Antidepressive Agents; Anxiety; Appetite Regulation; Bariatric Surgery; Body Mass Index; Bupropion; Cholecystokinin; Ciliary Neurotrophic Factor; Clinical Trials as Topic; Cyclobutanes; Depression; Diabetes Mellitus, Type 2; Female; Fluoxetine; Fructose; Ghrelin; Humans; Intra-Abdominal Fat; Islet Amyloid Polypeptide; Isoxazoles; Lactones; Leptin; Metabolic Syndrome; Metformin; Obesity; Obesity, Morbid; Orlistat; Oxyntomodulin; Peptide YY; Piperidines; Polycystic Ovary Syndrome; Pyrazoles; Rimonabant; Sertraline; Sleep Apnea, Obstructive; Surgical Procedures, Operative; Topiramate; Zonisamide	2008
Pharmacotherapy for obesity. Current atherosclerosis reports, 2007, Volume: 9, Issue:6 Topics: Amyloid; Anti-Obesity Agents; Appetite Depressants; Body Weight; Chronic Disease; Comorbidity; Cyclobutanes; Exenatide; Gastrointestinal Hormones; Humans; Islet Amyloid Polypeptide; Lactones; Leptin; Metformin; Obesity; Orlistat; Peptides; Piperidines; Pyrazoles; Randomized Controlled Trials as Topic; Rimonabant; Venoms	2007
Pediatric obesity: parallels with addiction and treatment recommendations. Harvard review of psychiatry, 2008, Volume: 16, Issue:2 Topics: Adolescent; Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Behavior Therapy; Child; Cognitive Behavioral Therapy; Cross-Sectional Studies; Diet, Reducing; Exercise; Humans; Hypoglycemic Agents; Lactones; Metformin; Motivation; Obesity; Orlistat; Prognosis; Risk Factors; Substance-Related Disorders	2008
Pharmacotherapy for obesity in menopausal women. Menopause international, 2008, Volume: 14, Issue:2 Topics: Anti-Obesity Agents; Bariatric Surgery; Cyclobutanes; Diabetes Mellitus, Type 2; Exenatide; Female; Humans; Hypoglycemic Agents; Lactones; Menopause; Metformin; Obesity; Orlistat; Peptides; Piperidines; Pyrazoles; Rimonabant; Risk Factors; Venoms	2008
Current and emerging therapies in nonalcoholic fatty liver disease. Seminars in liver disease, 2008, Volume: 28, Issue:4 Topics: Animals; Antioxidants; Bariatric Surgery; Body Mass Index; Cannabinoids; Cholagogues and Choleretics; Comorbidity; Fatty Liver; Glucagon-Like Peptide 1; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin Resistance; Lactones; Life Style; Metformin; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Thiazolidinediones; Treatment Outcome; Ursodeoxycholic Acid; Weight Loss	2008
[Dyspeptic syndrome associated with antidiabetic therapy]. Vnitrni lekarstvi, 2011, Volume: 57, Issue:4 Topics: Acarbose; Dyspepsia; Humans; Hypoglycemic Agents; Lactones; Metformin; Orlistat	2011
How can primary care providers manage pediatric obesity in the real world? Journal of the American Academy of Nurse Practitioners, 2011, Volume: 23, Issue:6 Topics: Adolescent; Anti-Obesity Agents; Bariatric Surgery; Body Mass Index; Child; Humans; Hypoglycemic Agents; Lactones; Life Style; Metformin; Obesity; Orlistat; Pediatrics; Physicians, Primary Care; Primary Health Care; Risk Factors	2011
The clinical treatment of childhood obesity. Indian journal of pediatrics, 2013, Volume: 80 Suppl 1 Topics: Adolescent; Bariatric Surgery; Behavior Therapy; Child; Child, Preschool; Combined Modality Therapy; Cooperative Behavior; Cyclobutanes; Energy Intake; Evidence-Based Medicine; Humans; Infant; Interdisciplinary Communication; Lactones; Life Style; Metformin; Motor Activity; Orlistat; Overweight; Pediatric Obesity; Pediatrics; Physician's Role; Practice Guidelines as Topic; Risk Factors; Young Adult	2013
Obesity and diabetes. Handbook of experimental pharmacology, 2012, Issue:214 Topics: Animals; Cyclobutanes; Diabetes Mellitus; Female; Humans; Incretins; Insulin; Lactones; Male; Metformin; Obesity; Orlistat; Piperidines; Pyrazoles; Rimonabant; Sex Characteristics; Sulfonylurea Compounds	2012
The effect of antiobesity drugs on waist circumference: a mixed treatment comparison. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:3 Topics: Anti-Obesity Agents; Benzazepines; Body Mass Index; Combined Modality Therapy; Drug Administration Schedule; Female; Humans; Lactones; Male; Metformin; Obesity; Orlistat; Risk Reduction Behavior; Treatment Outcome; Waist Circumference; Weight Loss	2014
Systematic review with meta-analysis: non-alcoholic steatohepatitis - a case for personalised treatment based on pathogenic targets. Alimentary pharmacology & therapeutics, 2014, Volume: 39, Issue:1 Topics: Bariatric Surgery; Fatty Liver; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Metabolic Syndrome; Metformin; Non-alcoholic Fatty Liver Disease; Orlistat; Precision Medicine; Thiazolidinediones; Ursodeoxycholic Acid; Vitamin E; Weight Loss	2014
Obesity and polycystic ovary syndrome. Minerva endocrinologica, 2015, Volume: 40, Issue:1 Topics: Adipokines; Bariatric Surgery; Combined Modality Therapy; Comorbidity; Diet, Reducing; Exercise Therapy; Female; Glucagon-Like Peptide 1; Gonadal Steroid Hormones; Humans; Hyperandrogenism; Inflammation; Insulin Resistance; Lactones; Life Style; Metformin; Models, Biological; Motivation; Obesity; Obesity, Abdominal; Orlistat; Polycystic Ovary Syndrome; Prevalence; Sympathetic Nervous System; Weight Loss	2015
Current Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. Clinics in liver disease, 2016, Volume: 20, Issue:2 Topics: Angiotensin Receptor Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anti-Obesity Agents; Anticholesteremic Agents; Antioxidants; Cannabinoid Receptor Antagonists; Cholagogues and Choleretics; Fatty Acids, Omega-3; Glucagon-Like Peptide-1 Receptor; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Metformin; Non-alcoholic Fatty Liver Disease; Orlistat; Pentoxifylline; Piperidines; Probiotics; Pyrazoles; Rimonabant; Synbiotics; Thiazolidinediones; Ursodeoxycholic Acid; Vitamin E	2016
Effects of orlistat vs. metformin on weight loss-related clinical variables in women with PCOS: systematic review and meta-analysis. International journal of clinical practice, 2016, Volume: 70, Issue:6 Topics: Anti-Obesity Agents; Female; Humans; Lactones; Metformin; Obesity, Morbid; Orlistat; Polycystic Ovary Syndrome	2016
Gastrointestinal Conditions in the Obese Patient. Adolescent medicine: state of the art reviews, 2016,Spring, Volume: 27, Issue:1 Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Anti-Obesity Agents; Constipation; Contraceptives, Oral, Combined; Diabetes Mellitus, Type 2; Digestive System Diseases; Fecal Incontinence; Gallstones; Gastroesophageal Reflux; Humans; Hypoglycemic Agents; Lactones; Metformin; Non-alcoholic Fatty Liver Disease; Orlistat; Pancreatitis; Pediatric Obesity	2016
Drug interventions for the treatment of obesity in children and adolescents. The Cochrane database of systematic reviews, 2016, Nov-29, Volume: 11 Topics: Adolescent; Anti-Obesity Agents; Body Mass Index; Child; Cyclobutanes; Fluoxetine; Humans; Lactones; Metformin; Orlistat; Pediatric Obesity; Randomized Controlled Trials as Topic	2016
Treatment of Pediatric Obesity: An Umbrella Systematic Review. The Journal of clinical endocrinology and metabolism, 2017, 03-01, Volume: 102, Issue:3 Topics: Adolescent; Anti-Obesity Agents; Appetite Depressants; Bariatric Surgery; Behavior Therapy; Blood Glucose; Blood Pressure; Body Mass Index; Child; Cholesterol, HDL; Cyclobutanes; Diet Therapy; Diet, Carbohydrate-Restricted; Diet, Fat-Restricted; Exercise; Exercise Therapy; Gastrectomy; Gastric Bypass; Humans; Hypoglycemic Agents; Lactones; Metformin; Orlistat; Patient Education as Topic; Pediatric Obesity; Treatment Outcome; Triglycerides; Waist Circumference	2017
Screening for Obesity and Intervention for Weight Management in Children and Adolescents: Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA, 2017, Jun-20, Volume: 317, Issue:23 Topics: Adolescent; Advisory Committees; Anti-Obesity Agents; Body Mass Index; Body Weight; Child; Child, Preschool; Humans; Hypoglycemic Agents; Lactones; Mass Screening; Metformin; Non-Randomized Controlled Trials as Topic; Orlistat; Overweight; Pediatric Obesity; Randomized Controlled Trials as Topic; United States; Weight Loss	2017
The Fatty Acid Lipid Metabolism Nexus in COVID-19. Viruses, 2021, Jan-11, Volume: 13, Issue:1 Topics: AMP-Activated Protein Kinases; Antiviral Agents; COVID-19; COVID-19 Drug Treatment; Digestive System; Fatty Acid Synthases; Fatty Acids; Humans; Lipid Metabolism; Metformin; Obesity; Orlistat; SARS-CoV-2; Viral Proteins; Virus Assembly; Virus Replication	2021
Molecular exploration of combinational therapy of orlistat with metformin prevents the COVID-19 consequences in obese diabetic patients. European review for medical and pharmacological sciences, 2021, Volume: 25, Issue:2 Topics: Anti-Obesity Agents; COVID-19; Diabetes Mellitus; Drug Therapy, Combination; Humans; Hypoglycemic Agents; Metformin; Obesity; Orlistat	2021
Impact of pharmacological interventions on anthropometric indices in women with polycystic ovary syndrome: A systematic review and meta-analysis of randomized controlled trials. Clinical endocrinology, 2022, Volume: 96, Issue:6 Topics: Acarbose; Body Weight; Female; Humans; Hypoglycemic Agents; Metformin; Orlistat; Pioglitazone; Polycystic Ovary Syndrome; Randomized Controlled Trials as Topic; Rosiglitazone	2022
Comparison of weight loss and adverse events of obesity drugs in children and adolescents: a systematic review and meta-analysis. Expert review of clinical pharmacology, 2022, Volume: 15, Issue:9 Topics: Adolescent; Anti-Obesity Agents; Child; Exenatide; Humans; Liraglutide; Metformin; Obesity; Orlistat; Topiramate; Weight Loss	2022

Trials

17 trial(s) available for metformin and orlistat

Article	Year
Evaluation of the safety and efficacy of sibutramine, orlistat and metformin in the treatment of obesity. Diabetes, obesity & metabolism, 2002, Volume: 4, Issue:1 Topics: Adult; Anti-Obesity Agents; Appetite Depressants; Blood Glucose; Body Mass Index; Body Weight; Cyclobutanes; Diabetes Mellitus; Female; Humans; Hypoglycemic Agents; Lactones; Metformin; Obesity; Orlistat; Postprandial Period; Safety; Treatment Outcome; Weight Loss	2002
Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes care, 2002, Volume: 25, Issue:7 Topics: Adult; Aged; Anti-Obesity Agents; Blood Glucose; Blood Pressure; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Humans; Hypoglycemic Agents; Lactones; Lipoproteins; Metformin; Middle Aged; Missouri; Obesity; Orlistat; Placebos; Racial Groups	2002
Comparison of the effect of orlistat vs orlistat plus metformin on weight loss and insulin resistance in obese women. International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity, 2004, Volume: 28, Issue:8 Topics: Adult; Dietary Fats; Drug Administration Schedule; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Intestinal Absorption; Lactones; Lipase; Metformin; Middle Aged; Obesity; Orlistat; Prospective Studies; Statistics, Nonparametric	2004
Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. The Journal of clinical endocrinology and metabolism, 2005, Volume: 90, Issue:2 Topics: Adult; Blood Pressure; Body Mass Index; Body Weight; Cholesterol; Enzyme Inhibitors; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Lipoproteins; Metformin; Orlistat; Polycystic Ovary Syndrome; Testosterone; Weight Loss; White People	2005
A randomized study of orlistat in combination with a weight management programme in obese patients with Type 2 diabetes treated with metformin. Diabetic medicine : a journal of the British Diabetic Association, 2005, Volume: 22, Issue:5 Topics: Adult; Aged; Anthropometry; Anti-Obesity Agents; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Diet, Reducing; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lactones; Male; Metformin; Middle Aged; Obesity; Orlistat; Weight Loss	2005
Inflammatory markers and the metabolic syndrome. Atherosclerosis, 2005, Volume: 183, Issue:1 Topics: Antihypertensive Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Fibrinogen; Heptanoic Acids; Humans; Hypolipidemic Agents; Inflammation; Lactones; Leukocyte Count; Metabolic Syndrome; Metformin; Orlistat; Prospective Studies; Pyrroles; Treatment Outcome	2005
Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Clinical endocrinology, 2009, Volume: 70, Issue:2 Topics: Adult; Anti-Obesity Agents; Body Mass Index; Female; Humans; Hyperandrogenism; Hypoglycemic Agents; Insulin; Insulin Resistance; Lactones; Metformin; Orlistat; Pioglitazone; Polycystic Ovary Syndrome; Thiazolidinediones; Treatment Outcome	2009
An RCT of metformin versus orlistat for the management of obese anovulatory women. Human reproduction (Oxford, England), 2009, Volume: 24, Issue:4 Topics: Adolescent; Adult; Androgens; Anovulation; Anti-Obesity Agents; Female; Humans; Hypoglycemic Agents; Lactones; Luteinizing Hormone; Metformin; Obesity; Orlistat; Ovulation; Weight Loss; Young Adult	2009
Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). Obesity (Silver Spring, Md.), 2010, Volume: 18, Issue:1 Topics: Adolescent; Adult; Aged; Benzoxazines; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Intention to Treat Analysis; Lactones; Lipase; Male; Metformin; Middle Aged; Obesity; Orlistat; Patient Selection; Treatment Outcome; Weight Loss	2010
The effects of metformin or orlistat on obese women with polycystic ovary syndrome: a prospective randomized open-label study. Journal of assisted reproduction and genetics, 2011, Volume: 28, Issue:7 Topics: Adult; Anti-Obesity Agents; Body Mass Index; Body Weight; Female; Humans; Hypoglycemic Agents; Lactones; Lipids; Metformin; Obesity; Orlistat; Ovulation; Polycystic Ovary Syndrome; Testosterone	2011
Weight loss significantly reduces serum lipocalin-2 levels in overweight and obese women with polycystic ovary syndrome. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2012, Volume: 28, Issue:1 Topics: Acute-Phase Proteins; Adolescent; Adult; Anti-Obesity Agents; Caloric Restriction; Combined Modality Therapy; Cyclobutanes; Down-Regulation; Exercise Therapy; Female; Humans; Lactones; Lipocalin-2; Lipocalins; Metformin; Obesity; Orlistat; Overweight; Polycystic Ovary Syndrome; Proto-Oncogene Proteins; Weight Loss; Young Adult	2012
Improvement of serum adiponectin and leptin concentrations: effects of a low-calorie or isocaloric diet combined with metformin or orlistat - a prospective randomized open-label trial. European review for medical and pharmacological sciences, 2016, Volume: 20, Issue:18 Topics: Adiponectin; Aged; Caloric Restriction; Diet, Reducing; Female; Humans; Hypoglycemic Agents; Lactones; Leptin; Metformin; Middle Aged; Obesity; Orlistat; Postmenopause; Prospective Studies; Weight Loss	2016
Endocannabinoid receptor blockade reduces alanine aminotransferase in polycystic ovary syndrome independent of weight loss. BMC endocrine disorders, 2017, Jul-14, Volume: 17, Issue:1 Topics: Alanine Transaminase; Anti-Obesity Agents; Body Mass Index; Cannabinoid Receptor Antagonists; Case-Control Studies; Female; Follow-Up Studies; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Liver Diseases; Metformin; Obesity; Orlistat; Pioglitazone; Piperidines; Polycystic Ovary Syndrome; Prognosis; Pyrazoles; Receptor, Cannabinoid, CB1; Retrospective Studies; Rimonabant; Thiazolidinediones; Weight Loss	2017
Effect of Diane-35, alone or in combination with orlistat or metformin in Chinese polycystic ovary syndrome patients. Archives of gynecology and obstetrics, 2018, Volume: 297, Issue:6 Topics: Adipose Tissue; Adult; Androgen Antagonists; Androgens; Cyproterone Acetate; Drug Combinations; Ethinyl Estradiol; Female; Humans; Insulin Resistance; Metformin; Obesity; Orlistat; Overweight; Polycystic Ovary Syndrome; Treatment Outcome	2018
The influence of orlistat, metformin and diet on serum levels of insulin-like growth factor-1 in obeses women with and without insulin resistance. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, 2018, Volume: 69, Issue:5 Topics: Adult; Anti-Obesity Agents; Caloric Restriction; Diet; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Insulin-Like Growth Factor I; Intra-Abdominal Fat; Metformin; Obesity; Orlistat; Premenopause	2018
[Effects of orlistat and metformin on metabolism and gonadal function in overweight or obese patients with polycystic ovary syndrome]. Zhonghua nei ke za zhi, 2021, Dec-01, Volume: 60, Issue:12 Topics: Body Mass Index; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Metformin; Obesity; Orlistat; Overweight; Polycystic Ovary Syndrome	2021
Significance of Orlistat in management of dyslipidemia, systolic blood pressure and body mass index. European review for medical and pharmacological sciences, 2022, Volume: 26, Issue:22 Topics: Blood Pressure; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Diabetes Mellitus, Type 2; Dyslipidemias; Follow-Up Studies; Humans; Metformin; Orlistat; Retrospective Studies; Triglycerides	2022

Other Studies

15 other study(ies) available for metformin and orlistat

Article	Year
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. Toxicological sciences : an official journal of the Society of Toxicology, 2013, Volume: 136, Issue:1 Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests	2013
Obesity and Type 2 diabetes mellitus. Diabetic medicine : a journal of the British Diabetic Association, 2000, Volume: 17, Issue:5 Topics: Anti-Obesity Agents; Blood Glucose; Body Mass Index; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Lactones; Male; Metformin; Middle Aged; Obesity; Orlistat; Weight Loss	2000
Case study: metformin-associated lactic acidosis: could orlistat be relevant? Diabetes care, 2003, Volume: 26, Issue:8 Topics: Acidosis, Lactic; Anti-Obesity Agents; Anti-Ulcer Agents; Cimetidine; Drug Interactions; Female; Humans; Hypoglycemic Agents; Lactones; Metformin; Middle Aged; Orlistat	2003
Management of the overweight patient with Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2003, Volume: 20 Suppl 4 Topics: Anti-Obesity Agents; Cyclobutanes; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Female; Humans; Hypoglycemic Agents; Lactones; Metformin; Middle Aged; Obesity; Orlistat; Selective Serotonin Reuptake Inhibitors; Sulfonylurea Compounds	2003
Improvement of glycaemic control with rebound following orlistat initiation and cessation associated with minimal weight change. Diabetic medicine : a journal of the British Diabetic Association, 2005, Volume: 22, Issue:3 Topics: Diabetes Mellitus, Type 2; Female; Glycated Hemoglobin; Guideline Adherence; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Insulin; Lactones; Metformin; Middle Aged; Obesity; Orlistat; Practice Guidelines as Topic; Weight Loss	2005
Identification and treatment of prediabetes to prevent progression to type 2 diabetes. Clinical cornerstone, 2008, Volume: 9, Issue:2 Topics: Acarbose; Anti-Obesity Agents; Clinical Trials as Topic; Diabetes Complications; Diabetes Mellitus, Type 2; Disease Progression; Humans; Hypoglycemic Agents; Lactones; Life Style; Metformin; Orlistat; Prediabetic State; Thiazolidinediones	2008
The effect of weight loss and treatment with metformin on serum vaspin levels in women with polycystic ovary syndrome. Endocrine journal, 2011, Volume: 58, Issue:4 Topics: Adolescent; Adult; Body Mass Index; Cyclobutanes; Diet, Reducing; Female; Humans; Lactones; Metformin; Orlistat; Overweight; Polycystic Ovary Syndrome; Serpins; Weight Loss	2011
Drug treatment of obesity. The Psychiatric clinics of North America, 2011, Volume: 34, Issue:4 Topics: Adolescent; Adult; Anti-Obesity Agents; Antidepressive Agents, Second-Generation; Body Weight; Bupropion; Child; Drug Approval; Drug Combinations; Energy Intake; Exenatide; Female; Fructose; Humans; Hypoglycemic Agents; Islet Amyloid Polypeptide; Lactones; Male; Metformin; Naltrexone; Narcotic Antagonists; Obesity; Orlistat; Patient Compliance; Peptides; Randomized Controlled Trials as Topic; Sympathomimetics; Topiramate; United States; United States Food and Drug Administration; Venoms	2011
Adolescent experiences of anti-obesity drugs. Clinical obesity, 2015, Volume: 5, Issue:3 Topics: Adolescent; Anti-Obesity Agents; Child; Comprehension; Drug Substitution; Fear; Female; Humans; Lactones; Male; Medication Adherence; Metformin; Motivation; Orlistat; Patient Satisfaction; Pediatric Obesity; Physician-Patient Relations; Self Concept	2015
Should family physicians prescribe medication for obesity? NO. Canadian family physician Medecin de famille canadien, 2017, Volume: 63, Issue:2 Topics: Anti-Obesity Agents; Body Mass Index; Family Practice; Humans; Lactones; Liraglutide; Male; Metformin; Obesity; Orlistat; Practice Guidelines as Topic; Practice Patterns, Physicians'	2017
Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, 2018, Volume: 34, Issue:5 Topics: Adult; Anti-Obesity Agents; Cyproterone Acetate; Drug Combinations; Drug Therapy, Combination; Ethinyl Estradiol; Female; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Metformin; Obesity; Orlistat; Overweight; Polycystic Ovary Syndrome; Young Adult	2018
Metainflammation in COVID-19. Endocrine, metabolic & immune disorders drug targets, 2022, Volume: 22, Issue:12 Topics: Aged; Angiotensin-Converting Enzyme 2; COVID-19; Dipeptidyl Peptidase 4; Eplerenone; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Metformin; Obesity; Orlistat; Peptidyl-Dipeptidase A; SARS-CoV-2; Spironolactone; Thiazolidinediones	2022
Obesity management: Attitudes and practice of Italian endocrinologists. Frontiers in endocrinology, 2022, Volume: 13 Topics: Anti-Obesity Agents; Endocrinologists; Humans; Metformin; Obesity; Orlistat	2022
Comparison of orlistat and orlistat plus metformin therapy between diabetic and nondiabetic groups. Revista da Associacao Medica Brasileira (1992), 2023, Volume: 69, Issue:7 Topics: Adult; Anti-Obesity Agents; Diabetes Mellitus, Type 2; Female; Humans; Lactones; Male; Metformin; Middle Aged; Orlistat; Weight Loss	2023